TEL AVIV, Israel, March  19, 2026  (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the &#34;Investors&#34; page on its website.  Q1 2026

TEVA

Teva Releases Q1 2026 Aide Memoire

Teva Pharmaceutical Releases Q1 2026 Aide Memoire Ahead of Earnings

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>TEL AVIV, Israel, March  19, 2026  (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the &amp;#34;Investors&amp;#34; page on its website.  Q1 2026</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Teva Pharmaceutical has released its Q1 2026 Aide Memoire, providing insights ahead of its earnings report scheduled for April 29, 2026. Investors should watch for the results, as they may indicate the success of Teva’s transformation into an innovative biopharmaceutical leader.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Teva&#039;s Q1 2026 Aide Memoire is now available to investors.</li><li>Results are expected on April 29, 2026, at 7am ET.</li><li>Document consolidates previous public information for investor assistance.</li><li>Teva continues transforming into a leading innovative biopharmaceutical company.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Teva Pharmaceutical Industries Ltd. (TEVA)</strong>: Teva&#039;s transition strategy could alter its market position.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This press release falls under Corporate Developments as it highlights Teva&#039;s strategic focus on innovation and informs investors ahead of critical earnings, positioning TEVA for potential investment interest.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Earnings results on April 29 could significantly impact TEVA&#039;s stock price.</li><li>Investors should monitor management&#039;s guidance during the upcoming conference call.</li><li>Teva&#039;s shift toward innovation may attract analyst upgrades post-earnings.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Teva&#039;s Q1 2026 results release: April 29, 2026, at 7am ET.</li><li>Aide Memoire compiled with information from previous results and management insights.</li><li>Teva aims to lead in innovative biopharmaceuticals alongside generics.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying TEVA shares ahead of Q1 2026 results for potential upside.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>TEL AVIV, Israel, March  19, 2026  (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the "Investors" page on its website.</p>  <p><span><a href="https://www.globenewswire.com/Tracker?data=iTnzQ63thJPFj5xWmrk7lTY0PlqXEncbqVvM-QZurtVUvfRwoNQcvpY-h3LR_5v4A8KjU9gjwbKWhpYQ-VcxWxLJFoHsrO267k56iptS1D9MNXPoHSeEE7IQDenpMW8T" target="_blank">Q</a></span><span><a href="https://www.globenewswire.com/Tracker?data=HsayudYh-v1uqXQDTgjDcM3pndq_GopzEX1-KylywJJuDAX-v_Eah5Ae5Aqu-hpQ2Sver6x_spCSZNbhmOR-500jfPn2d-YkNfoRPQyRgq99Pvn-C703jxsn5Jsw0VjB" target="_blank">1</a></span><span><a href="https://www.globenewswire.com/Tracker?data=H3ZKVAdyHHLf9ODP6HyySqqDJXSuPGK33HZdydO7wDRxARRN5ZjCjZ02PGYU3jX6lH25ik_ohsaBiM9-twr7ve13cplEIbJ2sLNRV1iI_KFXNE3dPLwZ6hSHIGfUNUhMwwou4B6MKENYsOyOTVLdBQ==" target="_blank"> 202</a></span><span><a href="https://www.globenewswire.com/Tracker?data=UzTXrIithFqRRcQU47gNfRVuCO0KdmASA0ImN8_D2gFZfs7RMoZwSgNa1ugYvcwE2fkwQ1gk0yVIOswfTYpFwl7ZBRvVH5539mHEN6LGQ45FS2sMKO8CHKCbzWWkH1q7" target="_blank">6</a></span><span><a href="https://www.globenewswire.com/Tracker?data=DIf44NlmDuk6h7F1_fz2_fTFz_EJs8DHeKIFJ1J9bHa-efU-M9xCWbX0RbcCOZpCccWWqGsy-sazLOeT0ZEqS_uUdZYInIc9Bpmq87pzr1qntUPqf-B9_qsHp-4lJfgzdMSpNS5M4CToGJV5akb4DQ==" target="_blank"> Aide Memoire</a></span></p>  <p>Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of first quarter 2026 results, which are expected to be released on Wednesday, April 29, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources.</p>  <p align="justify"><strong>About Teva</strong></p>  <p align="justify">Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit <span><a href="https://www.globenewswire.com/Tracker?data=hFUJCnp9iHakub8h3n6DSIzgpbpsU86bWp4zLgWEYTssOlwrPL7ciK4Ffn6fSZpw8fLUlioSMNtvw01t4gCOVk6dJYcpjYxCqfsOv37IrUey4qCnE_u4vxrQHKVRDuafWR2zNTU6IhxLuXlJKTR_4-8QAX_CuvuhzskZH1VSDuo6VBnsDQ_mlAiOSWyZpdzNv070ZFAMt4Jk9QZfG8BTb1zXt7hmgg7nEcTRUYOKkXBpeIhjSb7YUe1gErK6Ofa2Ka1f2WfeNxQ4nJkRRwbkqm6xnj9-LQb0A9tG01l6-6CSLnYRM1ytD-OnHmuX_zzpnu-UitYL2VLJhvDW9JFnuA1NoL21o7g5vOgzHzk-WIenpsd376Ysuwm399TIvMiRFSBIV0HWoWpIHneu0zdZLSEr62sBok5xb_ZZ6UulXfIWyn9YOWP4-xLLs0zkG9nxdman5Wh_8gBilfNgPd03LfrTlRh2NTsE1y8LlC4fZCUgwJ5OW6qjmzr8nqBcPv5Pm4uIJdqheq_drCcrVRPsKW1eKvp7V6IMcJhuzHLvfQvB90JqkbTARSZZUZtDFa8Auvi4nj_6EWyML4ccuPkT9ZZuDboH6iyJjZxEty3obPfMCpif-BFQg6K6vhzcrWZI" target="_blank">www.tevapharm.com</a></span>.</p>  <p align="justify"><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>  <p align="left">This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned &#34;Risk Factors" and "Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.<br></br></p>  <p align="justify"><strong>Teva Media Inquiries<br></br></strong><span><a href="https://www.globenewswire.com/Tracker?data=yBMZBGeQsY41XsXmmpIhfJRuZuB8y2TJZMAAey6ODV5vgSHNVZf74LL-nodbvSbWhpDOSUw_JYIeZHXow5D8-a1KXyg7WYZRZSrRzZf5i-CpiiBPnx7XCOBbSgdy9fQBCynIOKkoj-QH0bijd4ukIBoDe7r59jG4ZSPBK4YOhYs=" target="_blank"><strong>TevaCommunicationsNorthAmerica@tevapharm.com</strong></a></span></p>  <p><strong>Teva Investor Relations Inquiries<br></br></strong><span><a href="https://www.globenewswire.com/Tracker?data=yBMZBGeQsY41XsXmmpIhfAQLX3JNK7JYikXo2S5rrB5ozfAWPMi5UnPgMkF3gwVQer0oY7DnYZzDODLS8QLNINxNeaItlNuLJCmOaY5cRKQ=" target="_blank"><strong>TevaIR@Tevapharm.com</strong></a></span></p>  <p align="left" dir="RTL" style="text-align: left;"><br></br></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE3MTE5OSM0MDIzNjEyMDgjMjAwMzA3Nw=="></img> <br></br><img alt="" src="https://ml-eu.globenewswire.com/media/NTJlNzA2NGItMzhhNS00NjhhLWI1OTUtMTZlMmQwNTI4OGM5LTEwMTQ2NTAtMjAyNi0wMy0xOS1lbg==/tiny/Teva-Pharmaceutical-Industries.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/c2001734-949b-4cc2-8021-b4b64eda1f13"><img src="https://ml-eu.globenewswire.com/media/c2001734-949b-4cc2-8021-b4b64eda1f13/small/teva-rgb-jpeg-jpg.jpg" border="0" width="150" height="54" alt="Primary Logo"></img></a></p>

Teva Pharmaceutical has released its Q1 2026 Aide Memoire, providing insights ahead of its earnings report scheduled for April 29, 2026. Investors should watch for the results, as they may indicate the success of Teva’s transformation into an innovative biopharmaceutical leader.

Teva Releases Q1 2026 Aide Memoire

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News